Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three months ended Year ended December 31, December 31, 2008 2007 2008 2007 (unaudited) Revenue $28 $28 $111 $743 Operating expenses: Research and development 10,755 21,743 50,086 76,523 General and administrative 4,783 5,382 20,503 25,839 Total operating expenses 15,538 27,125 70,589 102,362 Loss from operations (15,510) (27,097) (70,478) (101,619) Interest income 712 1,717 3,619 6,461 Interest expense (1,161) (1,571) (5,156) (4,106) Gain from valuation of warrant liability 7,122 - 371 - Net loss ($8,837) ($26,951) ($71,644) ($99,264) Basic and diluted net loss per share ($0.09) ($0.32) ($0.79) ($1.20) Shares used in computation of basic and diluted net loss per share 95,109 83,051 90,357 82,531 December 31, December 31, 2008 2007 Balance Sheet Data: Cash and cash equivalents $59,523 $75,721 Short-term investments 45,638 27,115 Long-term investments 3,386 17,739 Total assets 147,204 161,662 Warrant liability 14,190 - Convertible senior subordinated Notes 85,2
'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... company developing what it believes to be a novel tool ... tax credits from the State of Wisconsin to ... instead has raised a total of $385,000 from a combination ... to CEO Larry Wells, state law prohibits the company from ...
... Wis. - Last week, the nation marked ... stem cell research. Those restrictions have unquestionably set back ... say. , ,When Congress passed legislation that would ... among families whose loved ones are suffering from a ...
... - After months of speculation, North Prairie Productions, ... selected a site for a biodiesel plant that will produce ... will begin construction on the $42 million facility next spring ... side, where it will relocate its Waterloo offices. , ...
Cached Biology Technology:NovaScan decides against tax credits 2Stem cell research holds the promise for tomorrow 2Stem cell research holds the promise for tomorrow 3Evansville site chosen for biodiesel plant 2
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... won the "Most Creative Visualization" award in the "commercial" ... achievement we are extremely proud of. iDEA is Illumina,s ... new and creative visualization and data analysis techniques. ... very first moment we heard about it. Genomatix is ...
... Kan. -- Preliminary research at Kansas State University may make ... scientists believe that cellulose, the most common organic compound on ... biofuels -- if a procedure to effectively break it down ... gives plants their rigidity. Kathrin Schrick, assistant professor in ...
... This press release is available in Spanish ... waters of the European Atlantic Ocean and, nevertheless, resists stock ... the mistakes made by humans. Ms Nerea Goikoetxea, a researcher ... the population dynamics of the northern European hake population, observing ...
Cached Biology News:Learning secrets of world's most common organic compound driving research for biofuels 2Hake population has withstood overfishing, thanks to the warming of the sea 2Hake population has withstood overfishing, thanks to the warming of the sea 3